摘要
目的:探讨清血消脂方调节脂肪酸结合蛋白4(FABP4)和过氧化物酶增殖物激活受体(PPAR)表达对动脉粥样硬化小鼠的干预作用。方法:选取45只ApoE-/-小鼠经高脂喂养9周后,随机分为模型组(n=15)、立普妥(阿托伐他汀钙)组(n=15)、清血消脂方组(n=15);继续高脂喂养并药物干预9周后,测其血脂及血清同型半胱氨酸水平,主动脉斑块面积与斑块中胶原纤维含量;同时,测定FABP4、PPARα与PPARγ在肝脏及主动脉中mRNA及蛋白表达水平。结果:与模型组比较,清血消脂方可显著降低血清三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)与血清同型半胱氨酸(Hcy)水平,差异有统计学意义(P<0.05),且明显缩小主动脉斑块相对面积,差异有统计学意义(P<0.05)。清血消脂方显著降低主动脉中FABP4的mRNA及蛋白表达(P<0.05),并促进PPARγmRNA及蛋白表达,差异有统计学意义(P<0.05);同时,清血消脂方可显著降低肝脏中FABP4的蛋白表达,并促进PPARγ的蛋白表达,差异有统计学意义(P<0.05)。结论:清血消脂方对动脉粥样硬化具有一定的防治作用,其机制可能与显著降低主动脉与肝脏中FABP4的mRNA及蛋白表达,并促进PPARγ的表达有关。
Objective:To explore the therapeutic mechanism of Qingxue Xiaozhi Formula(QXXZ)on atherosclerosis mice model via inhibiting FABP4 and promoting PPARγin the aorta and liver.Methods:A total of 45 ApoE-knockout(ApoE-/-)mice fed with high-fat diet for 9 weeks were randomly divided into a model group(n=15),a Lipitor group(n=15)and a QXXZ group(n=15).For an additional 9 weeks with high-fat diet and drug intervention,blood lipids and homocysteine(Hcy)in serum,plaque areas in aorta,and collagen fibers in plaques were determined.The mRNA and protein expression levels of FABP4,PPARαand PPARγin the liver and aorta were measured.Results:1)QXXZ significantly decreased the TGs,LDL-C and Hcy levels compared with the model group.And it significantly reduced the relative area of aortic plaque(P<0.05)2)QXXZ significantly reduced FABP4 protein expression levels in the aorta(P<0.05),and promoted PPARγmRNA and protein expression levels(P<0.05);at the same time,QXXZ can significantly reduce FABP4 protein expression levels in the liver and promote the protein expression of PPARγ(P<0.05).Conclusion:QXXZ has a certain preventive effect on atherosclerosis,and its mechanism may be related to significantly reducing the mRNA and protein expression levels of FABP4 in the aorta and liver,and promoting the expression of PPARγ.
作者
康群甫
周明学
张蕾
刘红旭
刘卫红
KANG Qunfu;ZHOU Mingxue;ZHANG Lei;LIU Hongxu;LIU Weihong(Cardiovascular Department,Shunyi Hospital,Beijing Traditional Chinese Medicine Hospital,Beijing 101300,China;Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University/Beijing Institute of Traditional Chinese Medicine, Beijing 100010,China;Cardiovascular Department,Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University, Beijing 100010,China)
出处
《世界中医药》
CAS
2021年第4期581-586,共6页
World Chinese Medicine
基金
国家自然科学基金项目(81573735)
北京市自然科学基金项目(7142037)。
关键词
动脉粥样硬化
清血消脂方
脂肪酸结合蛋白4
过氧化物酶增殖物激活受体-α
过氧化物酶增殖物激活受体-γ
APOE基因敲除小鼠
同型半胱氨酸
中医药
Atherosclerosis
Qingxue Xiaozhi Formula
Fatty acid binding protein 4(FABP4)
Peroxisome proliferator-activated receptor-α(PPARα)
Peroxisome proliferator-activated receptor-γ(PPARγ)
Peroxidase proliferator activated receptor-γ
ApoE-knockout mic
Homocysteine
Traditional Chinese Medicine(TCM)
